Diabetes
-
Permission granted by CMR Surgical
Robots, AI and PFA: The top medtech Q&As of 2024
From challenging market leaders to the growing influence of artificial intelligence, medical device executives had a lot to discuss this year. Check out MedTech Dive’s top Q&As of 2024.
By Ricky Zipp • Dec. 20, 2024 -
Courtesy of Dexcom
Dexcom adds generative AI to over-the-counter CGMs
Dexcom this week began rolling out the feature, which analyzes data to provide personalized tips and recommendations.
By Elise Reuter • Dec. 18, 2024 -
AnkiHoglund via Getty Images
Embecta to cut 125 jobs after ending insulin patch pump
Embecta said its patch pump would require additions to be commercially competitive, and plans to use the funds saved to pay down debt.
By Elise Reuter • Dec. 6, 2024 -
Courtesy of EOFlow
Insulet awarded $452M in EOFlow patent fight
A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.
By Elise Reuter • Dec. 5, 2024 -
aprott via Getty Images
Biden administration proposes Medicare, Medicaid coverage of pricey weight loss drugs
About 7.4 million Americans with obesity could have insurance coverage for drugs like Wegovy if the Trump administration allows the rule to go into effect — at the cost of $40 billion to federal and state governments.
By Rebecca Pifer • Nov. 27, 2024 -
Permission granted by Embecta
Embecta discontinues insulin patch pump development
CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.”
By Elise Reuter • Nov. 26, 2024 -
Courtesy of Medtronic
Medtronic nets FDA nod for smart insulin pen app
The clearance paves the way for the launch of Medtronic’s Smart MDI system, which combines its InPen and Simplera continuous glucose monitor for people who take multiple daily insulin injections.
By Susan Kelly • Nov. 22, 2024 -
Courtesy of Ōura
Dexcom invests $75M in Ōura, agrees to integrate smart rings and CGMs
The partnership will support data flows that enable people who use both companies’ devices to track how glucose levels affect other health metrics.
By Nick Paul Taylor • Nov. 20, 2024 -
Permission granted by Abbott
Abbott opens plant in Ireland to boost Libre 3 sensor production
More than 800 people will be employed at the plant, which will make more Libre sensors than any of the company’s other facilities.
By Nick Paul Taylor • Nov. 19, 2024 -
Permission granted by Sequel Medtech
Dean Kamen, insulin pump pioneer, wants to shake up diabetes tech
Kamen and Sequel Med Tech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology in the Twiist device.
By Elise Reuter • Updated Nov. 25, 2024 -
Courtesy of Tandem Diabetes Care
Tandem, Insulet tout Type 2 expectations as tech attracts new users
Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while Tandem plans to file a Type 2 submission by year’s end.
By Ricky Zipp • Nov. 8, 2024 -
Permission granted by Dexcom
Dexcom chief commercial officer to retire
Teri Lawver is leaving the diabetes tech company during a challenging time, with sales slowing after a workforce restructuring.
By Elise Reuter • Oct. 25, 2024 -
Courtesy of Boston Scientific
Boston Scientific, Edwards and Dexcom usher in second week of earnings
Johnson & Johnson, Abbott and Intuitive Surgical made a mixed start to earnings season last week.
By Nick Paul Taylor • Oct. 22, 2024 -
Courtesy of Cue Health Press Kit
FDA labels Cue’s recall of COVID tests as Class II, revokes EUAs
Cue Health began the recall of nearly 250,000 COVID-19 test kits in May, shortly after the FDA advised people at home and healthcare professionals not to use the products.
By Nick Paul Taylor • Oct. 17, 2024 -
Permission granted by Abbott
Abbott CEO sees ‘mass market potential’ for CGMs
Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.
By Ricky Zipp • Oct. 16, 2024 -
Mario Tama via Getty Images
J&J, Abbott and Intuitive kick off latest medtech earnings season
From pulsed field ablation to diabetes tech and surgical robots, the updates will provide an early look at how key medtech markets performed last quarter.
By Nick Paul Taylor • Oct. 14, 2024 -
Courtesy of Medtronic
Medtronic recalls Minimed insulin pumps for reduced battery life
The company said it received 170 reports of hyperglycemia and 11 reports of diabetic ketoacidosis in the U.S. that could be linked to the problem.
By Susan Kelly • Oct. 7, 2024 -
halbergman via Getty Images
Top medtech conferences in 2025
The lineup includes industrywide conferences and events covering the latest medtech trends in diabetes, orthopedics, cardiac care and surgical robotics.
By Ricky Zipp • Oct. 1, 2024 -
Permission granted by Abbott Laboratories
Abbott ramps up Libre 3 production amid shortages
Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.
By Elise Reuter • Sept. 20, 2024 -
Permission granted by Senseonics
Senseonics receives FDA clearance for one-year CGM
Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.
By Elise Reuter • Sept. 17, 2024 -
Permission granted by Roche
Roche to launch new CGM in Europe in ‘coming weeks’
Roche will roll out its Accu-Chek Smartguide in the Netherlands, Switzerland and Germany. The company hopes to stand out from competitors with features to predict hypoglycemia.
By Elise Reuter • Sept. 12, 2024 -
Permission granted by Abbott
Dexcom, Abbott OTC glucose sensors add to busy year for diabetes tech
New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.
By Ricky Zipp • Sept. 11, 2024 -
Courtesy of Abbott
Abbott debuts Lingo over-the-counter CGM in the US
Priced at $49 for one 14-day sensor, or $89 per month, Abbott’s offering is competitive with Dexcom’s Stelo sensor.
By Elise Reuter • Sept. 6, 2024 -
Permission granted by Abbott Laboratories
Abbott partners with maker of ‘bionic pancreas’
Abbott will integrate its latest glucose sensor with Beta Bionics’ automated insulin delivery system.
By Nick Paul Taylor • Sept. 5, 2024 -
Permission granted by Nasdaq
Embecta gets FDA nod for insulin patch pump
Embecta’s first patch pump features a larger insulin reservoir, based on feedback from people with Type 2 diabetes.
By Elise Reuter • Sept. 3, 2024
